5-hydroxymethylcytosine sequencing of plasma cell-free DNA identifies epigenomic features in prostate cancer patients receiving androgen deprivation therapies.

ABSTRACT:

Background

We evaluated whether 5hmC signatures in cell-free DNA (cfDNA) are associated with treatment failure to androgen-deprivation therapies (ADT) among men with hormone-naive prostate cancer.

Methods

We collected a total of 139 serial plasma samples from 55 prostate cancer patients receiving ADT at 3 time points including baseline (before initiating ADT, n = 55); 3 months (after initiating ADT, n = 55); and disease progression (n = 15) within 24 months or 24 months if no progression was detected (n = 14). We used selective chemical labeling sequencing to quantify 5hmC abundance across the genome and Kaplan-Meier analysis to assess survival association.

Results

Here we show a significant 5hmC difference in 1642 of 23433 genes between patients with and without prog

SUBMITTER: Li Q 

PROVIDER: S-EPMC11880319 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature